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Abstract (word limit 300) 
Background: When nerve transection is performed on adult rodents, a substantial population of 
neurons survives short-term disconnection from target, and the immune system supports this 
neuronal survival, however long-term survival remains unknown. Understanding the effects of 
permanent axotomy on cell body survival is important as target disconnection is the first 
pathological occurrence in fatal motoneuron diseases such as amyotrophic lateral sclerosis (ALS) 
and spinal muscular atrophy (SMA).  
Objective: The goal of this study was to determine if facial motoneurons (FMN) could survive 
permanent target disconnection up to 26 weeks post-operation (wpo) after facial nerve axotomy 
(FNA). In addition, the potentially additive effects of immunodeficiency and motoneuron disease 
on post-axotomy FMN survival were examined.  
Methods: This study included three wild type (WT) mouse strains (C57BL/6J, B6SJL, and 
FVB/NJ) and three experimental models (RAG-2-/-: immunodeficiency; mSOD1: ALS; Smn-/-
/SMN2+/+: SMA). All animals received a unilateral FNA, and FMN survival was quantified at 
early and extended post-operative timepoints. 
Results: In the C57BL/6J WT group, FMN survival significantly decreased at 10 wpo (55 ± 6%), 
and then remained stable out to 26 wpo (47 ± 6%). In the RAG-2-/- and mSOD1 groups, FMN 
death occurred much earlier at 4 wpo, and survival plateaued at approximately 50% at 10 wpo. 
The SMA model and other WT strains also exhibited approximately 50% FMN survival after 
FNA. 
Conclusion: These results indicate that immunodeficiency and motoneuron disease accelerate 
axotomy-induced neuron death, but do not increase total neuron death in the context of 
permanent target disconnection. This consistent finding of a target disconnection-resilient 
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motoneuron population is prevalent in other peripheral nerve injury models and in 
neurodegenerative disease models as well. Characterization of the distinct populations of 
vulnerable and resilient motoneurons may reveal new therapeutic approaches for injury and 
disease. 
 
Keywords: motoneuron; axotomy; amyotrophic lateral sclerosis; spinal muscular atrophy; 
neuron survival; peripheral nerve injury; motor neuron 
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1. Introduction 
Experimental models of peripheral nerve injury have been used for decades to understand 
cellular responses to injury and to identify new therapeutic approaches for neuroregeneration. 
Functional recovery from nerve injury requires survival of the neuron cell body, regrowth of its 
axon, and reconnection to a target, with neuron survival being the first component necessary for 
success (Hart, Terenghi, & Wiberg, 2008). Study of axotomized motoneurons (MN) is especially 
important given their exquisite reciprocal relationship with muscle, as both cell populations 
provide trophic support for each other’s survival, and disruption of this connection can lead to 
muscle atrophy and MN death.  
Factors that impact MN survival after target disconnection include species, age, severity 
of the injury, and distance of the injury from the cell body (Gu, Spasic, & Wu, 1997; Hart et al., 
2008; Moran & Graeber, 2004). In addition, our laboratory has determined that immune status 
also affects facial motoneuron (FMN) survival after facial nerve axotomy (FNA), in which nerve 
transection results in permanent target disconnection. Comparing wild type (WT) to the severe 
combined immunodeficient (scid) mouse model reveals that the immune system supports FMN 
survival at 4 weeks post-operation (wpo), but this neuroprotective effect is temporary, and FMN 
survival falls at 10 wpo, correlating with down-regulation of the immune activation (Serpe, 
Sanders, & Jones, 2000). This transient support only applies to approximately half of the FMN 
population; the other half of FMN are resilient to target disconnection regardless of immune 
status. 
Target disconnection is also a contributing factor in the MN disease amyotrophic lateral 
sclerosis (ALS), as loss of neuromuscular junctions is the earliest observed pathology, followed 
by retrograde axonal die-back that ultimately results in death of the MN cell body (Fischer et al., 
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2004). In the mutant superoxide dismutase 1 (mSOD1) mouse model of ALS, the disease process 
first affects lumbar MN, resulting in a total of 50% lumbar MN loss by endstage at 18-19 weeks 
of age (woa, Chiu et al., 1995). The MN disease process in the mSOD1 mouse ascends rostrally, 
and FMN loss is first detected at 16 weeks of age (Haulcomb et al., 2014). When FNA is 
superimposed on mSOD1 mice in the presymptomatic stage of disease at 8 woa, FMN death is 
observed earlier than WT at 4 wpo and remains stable at 8 wpo, reflecting a similar temporal 
pattern of target disconnection-induced MN death as observed in immunodeficient animals 
(Haulcomb et al., 2014). Together, these studies suggest that there exists a MN population that is 
resistant to both disease- and axotomy-induced MN death in mSOD1 mice. 
 Spinal muscular atrophy (SMA) is a genetic MN disease caused by a lack of functional 
survival motoneuron (SMN) protein, and the disease pathology also consists of an axonal die-
back process (Udina et al., 2017). The Smn-/-/SMN2+/+ mouse model of SMA recapitulates the 
human disease phenotype and has a lifespan of 9 – 15 months, and this transgenic mouse was 
included in this study as a second model of MN disease. At 12 months of age, there is about 60% 
MN survival in the lumbar spinal cord as a result of the disease process, again e a disease-
resilient MN population (Tsai, Tsai, Lin, Hwu, & Li, 2006). Only one study thus far has 
examined how an SMA mouse model responds to peripheral nerve injury using the Smn+/- SMA 
transgenic mouse model, which is the mildest model of SMA disease. Sciatic nerve axotomy of 
this model revealed no significant difference in axotomy-induced MN death (about 10% loss 
relative to uninjured control side) in the Smn+/- SMA model at 8 and 16 wpo relative to WT 
(Udina et al., 2017). There is evidence in the SMA disease model that there are both a disease- 
and axotomy-resilient MN population, mirroring the findings in the mSOD1 ALS mouse model.  
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 This persistent finding of neurons resilient to target disconnection has been documented 
in a plethora of publications reporting on other neuronal populations using a variety of peripheral 
nerve injury models (Hart et al., 2008). This study advances the field by addressing two 
questions: first, what are the long-term effects of permanent target disconnection on FMN 
survival, and second, how does immunodeficiency or MN disease further affect FMN survival 
after axotomy? To accomplish this goal, FMN survival after FNA was assessed in three WT 
strains: C57BL/6J, B6SJL, and FVB/NJ, and three experimental groups: the recombinase-
activating gene-2 knockout model of immunodeficiency (RAG-2-/-) on the C57BL/6J 
background, the mSOD1 on B6SJL background, and the Smn-/-/SMN2+/+ (SMA) on FVB/NJ 
background. Our data consistently reveal that approximately 50% of the FMN population is 
resilient to target disconnection, regardless of mouse strain, immune status, or concurrent MN 
disease. Further applications of this facial nerve injury model can lead to identification of 
neuroprotective factors that could be clinically applicable in the contexts of both traumatic nerve 
injury and neurodegenerative disease.  
 
2. Materials and Methods 
 
2.1 Animals and surgical procedure 
 
All animal handling and procedures were in compliance with the National Institutes of 
Health (NIH) guidelines and were approved by Indiana University School of Medicine’s 
Institutional Animal Care and Use Committee. The following strains of mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME): C57BL/6J (C57BL/6J WT, 
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RRID:IMSR_JAX:000664), B6(Cg)-Rag2tm1.1Cgn/J (RAG-2-/-, RRID:IMSR_JAX:008449), 
B6SJL F1/J (B6SJL WT, RRID:IMSR_JAX:100012), B6SJL-Tg(SOD1*G93A)1Gur/J (mSOD1, 
RRID:IMSR_JAX:002726). The FVB/NJ and Smn-/-/SMN2+/+ SMA mouse strains were bred in-
house and graciously provided by Drs. E.J. Androphy and S.K. Custer. These mice strains are 
also available through The Jackson Laboratory (FVB/NJ, RRID:IMSR_JAX:001800; FVB.Cg-
Smn1tm1Hung Tg(SMN2)2Hung/J, RRID:IMSR_JAX:005058). Normal, non-ovariectomized 
female mice were exclusively used in this study because male mice exhibit significant aggressive 
behavior post-operatively and require individual housing, which is detrimental to animal welfare.  
FNA was performed following previously published methods on 8 week old mice using 
aseptic technique (Serpe et al., 2000). In brief, the trunk of the facial nerve was exposed at its 
exit from the stylomastoid foramen and completely transected, and the stumps were separated to 
prevent reconnection. Right facial paralysis was confirmed by absent vibrissae movement and 
null eyeblink reflex to air puff stimuli. In all axotomized animals, no recovery of facial motor 
function was observed throughout the experimental timecourse. The left facial nerve was not 
operated on, allowing for the left facial motor nucleus to serve as a paired internal control. 
 
2.2 Facial motoneuron quantification and statistical analysis 
 
At the appropriate experimental endpoint (4, 6, 10, 18, or 26 wpo; n = 4-8/group/timepoint), 
animals were euthanized via CO2 inhalation and cervical dislocation, and the brain was removed 
and flash frozen. Tissue processing, thionin staining, and facial motoneuron counting procedures 
were executed following previously published protocols (Serpe et al., 2000). One-way ANOVA 
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and Tukey’s multiple comparisons tests, two-way ANOVA and Sidak’s multiple comparisons 
test, and unpaired t-tests were performed using Graphpad version 7.03.  
 
3. Results 
3.1. Long-term survival of axotomized facial motoneurons in C57BL/6J WT and immunodeficient 
RAG-2-/- mice 
 
 To determine the effects of time on axotomized FMN survival, 8 week old C57BL/6J WT 
mice received FNA, and FMN quantification was performed at 4, 10, 18, and 26 wpo. In the 
C57BL/6J WT, FMN survival was not significantly decreased relative to the control facial motor 
nucleus at 4 wpo (89 ± 2%). Significant FMN loss relative to control facial motor nucleus was 
observed at 10, 18, and 26 wpo (55 ± 6%, 44 ± 5%, 47 ± 6%, respectively, p < 0.001, for each), 
and no significant differences were observed between 10-26 wpo timepoints (Fig. 1A). Thus, a 
plateau in the WT group was reached by 10 weeks. 
 To identify if immunodeficiency had an added impact on long-term FMN survival after 
FNA, RAG-2-/- mice were next examined. Relative to the uninjured control facial motor nucleus, 
FMN survival was significantly decreased at 4 wpo (67 ± 4%, p < 0.001) and continued to 
decrease out to 10 wpo in RAG-2-/- mice (50 ± 6%, p = 0.04). FMN survival levels remained 
stable at 18 weeks after axotomy (53 ± 4%), with no significant difference relative to 10 wpo 
(Fig. 1A). 
 In comparing the two groups, RAG-2-/- mice exhibited significantly earlier FMN loss 
relative to C57BL/6J WT at 4 wpo (p = 0.007), and there were no differences detected at later 
timepoints. The findings in the RAG-2-/- group reflect what was observed in a previous study of 
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the Balb/c WT and RAG-2-/- on Balb/c background (Serpe et al., 2000). Prior work on FMN 
survival after FNA has only gone as far as 10 wpo, in which immunodeficient scid mice exhibit 
comparable FMN survival relative to the C.B-17 ICR WT strain (Serpe et al., 2000). Together, 
these findings suggest that there is a population of FMN whose early, transient survival depends 
on an intact immune system, and a second population of FMN exists for which immune status 
has no effect.  
 
3.2. Long-term survival of axotomized facial motoneurons in B6SJL WT and mSOD1 mice 
 
The impact of concurrent MN disease on long-term FMN survival after FNA was next 
examined. In the mSOD1 mouse model of ALS, hindlimb motor dysfunction develops at 13 
weeks of age (woa), and the mouse is moribund due to paralysis at approximately 18-19 woa 
(Chiu et al., 1995). In this study, FNA was performed in the pre-symptomatic stage at 8 woa, and 
animals were euthanized at 4 wpo (12 woa) and 10 wpo (18 woa), just before endstage. The 
B6SJL WT was included as a strain-matched control. 
 First, disease-induced MN loss was measured by quantifying FMN in the control facial 
motor nucleus in both B6SJL WT and mSOD1 groups. At 12 woa, still within the 
presymptomatic stage, there is no significant loss of FMN in the mSOD1 group relative to 
B6SJL WT (48 ± 3 vs. 45 ± 2 FMN/section). At 18 woa, near endstage, there is a significant 
disease-induced loss of FMN in the mSOD1 group relative to B6SJL WT (33 ± 4 vs. 54 ± 4 
FMN/section, p = 0.003, Fig 1B).  
Second, the effect of superimposing FNA on mSOD1 mice on FMN survival was 
quantified at early and late timepoints. In the B6SJL WT, FMN survival was not significantly 
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different from the control facial motor nucleus at 4 wpo (90 ± 3%), and a significant drop in 
FMN survival was observed at 10 wpo (56 ± 8%, p < 0.001; Fig. 1C). In the mSOD1 group, a 
significant decrease in FMN survival relative to the unoperated control side was observed at 4 
and 10 wpo (67 ± 3% and 56 ± 8%, p = 0.004 and 0.0003, respectively), and there was no 
statistically significant difference between 4 and 10 wpo (Fig. 1C). The mSOD1 group had a 
significant decrease in post-axotomy FMN survival at 4 wpo relative to B6SJL WT (p = 0.02). 
There was no difference in FMN survival between these groups at 10 wpo, suggesting that the 
resilient MN population remains unaffected by concurrent MN disease and target disconnection.  
  
3.3. FMN survival in a second model of motoneuron disease 
 
To further explore the effects of MN disease on FMN survival after FNA, the Smn-/-
/SMN2+/+ mouse model of SMA was also included in this study. This specific SMA mouse 
model develops motor symptoms at 36 woa, and lifespan ranges from 36-60 woa, which is a 
similar lifespan as the strain-matched FVB/NJ WT (Tsai et al., 2006). For this study, FNA was 
performed within the presymptomatic stage at 8 woa, and the 6 wpo timepoint (14 woa) was 
selected as an intermediary between 4 and 10 wpo used for previous groups in an effort to 
conserve animals.  
When the effects of SMA disease on FMN survival was quantified at 14 woa, there was 
no significant difference in the SMA group relative to the FVB/NJ WT (82 ± 4 vs. 71 ± 6, 
respectively, Fig. 1D). After FNA, the SMA group also had equivalent FMN survival compared 
to FVB/NJ WT at 6 wpo (64 ± 5% vs. 57 ± 3%, respectively, Fig. 1E). These findings indicate 
that the SMA MN disease does not augment axotomy-induced FMN death after FNA, similar to 
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the findings observed in the mSOD1 mouse model. This result reinforces the evidence for a MN 
population that is resilient in settings of both MN disease and axotomy-induced target 
disconnection. 
 
4.0 Discussion 
 
This study examined the long-term effects of axotomy-induced target disconnection on 
MN survival and determined if immunodeficiency or MN disease further affected survival. The 
first important finding from this study is that there is a MN population that survives permanent 
target disconnection for a prolonged length of time. Furthermore, this resilient population is 
persistent in the contexts of both immunodeficiency and MN disease. This study is also 
significant because, to our knowledge, this is the first study presenting post-axotomy MN 
survival data on the Smn-/-/SMN2+/+ mouse model of SMA, with the only other available data 
being from a sciatic nerve injury on the C57BL/6-Smn+/- model, which also found axotomy- and 
disease-resilient MN (Udina et al., 2017).  
This finding of a long-term resilient population of neurons after axotomy is apparent in 
other neuronal types as well (Hart et al., 2008). For example, 65% of sensory neurons survive 
sciatic nerve transection at 24 wpo (McKay Hart, Brannstrom, Wiberg, & Terenghi, 2002), 70% 
of motoneurons survive C7 spinal nerve transection at 16 wpo (Ma, Novikov, Wiberg, & 
Kellerth, 2001), and 65% of hypoglossal motor neurons survive axotomy at 52 wpo (Snider & 
Thanedar, 1989). The only known circumstances that result in near-total neuronal death after 
axotomy occur with nerve avulsion injuries or when axotomy is imposed on neonatal animals 
(Catapano et al., 2017; Gu et al., 1997).   
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 The presence of axotomy-vulnerable vs. -resilient FMN challenges the traditional 
understanding of neuronal physiology, in that trophic factors from target are required for cell 
body survival. From developmental and functional perspectives, FMN have been historically 
considered to be homogenous (Moran & Graeber, 2004). However, the results of this study 
clearly indicate the presence of two populations of FMN with diametrically-opposed responses to 
target disconnection in both WT and disease mouse models. Future work will focus on the 
elucidation of underlying mechanisms that define the fate-determining intrinsic steps occurring 
in the two distinct motoneuron pools. Previous studies determined that axotomy-induced FMN 
death is asymmetrically distributed throughout the facial motor nucleus, and careful stereotactic 
analysis may identify individual vulnerable or resilient MN (Canh, Serpe, Sanders, & Jones, 
2006). Identification of these different neuronal populations within the seemingly-homogeneous 
facial motor nucleus may lead to development of biomarkers that can be applied in 
neuroregenerative research. Extrinsic influences from microglia and astrocytes in the CNS or 
Schwann cells in the residual nerve will also be evaluated, as these cell responses to nerve injury 
are also heterogeneous and may differentially promote MN survival (Brushart et al., 2013; 
Liddelow et al., 2017; Mesnard, Alexander, Sanders, & Jones, 2010; Morganti, Riparip, & Rosi, 
2016; Scheib & Hoke, 2013). Identifying and harnessing the key mechanisms behind neuronal 
resiliency in axotomy and disease will significantly advance the development of therapies for 
patients. 
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Figure 1: Quantification of FMN survival in WT and experimental groups. A: Average percent 
FMN survival ± SEM comparing the axotomized (Ax) to uninjured control (C) facial motor 
nucleus at 4, 10, 18, and 26 weeks post-operation (wpo). B: Average FMN counts ± SEM per 25 
µm section of the uninjured control facial motor nucleus at 12 and 18 weeks of age (woa). C: 
Average percent FMN survival ± SEM, comparing the Ax to C facial motor nucleus at 4 and 10 
wpo, corresponding with 12 and 18 woa, respectively. D: Average FMN counts ± SEM per 25 
µm section of the uninjured control facial motor nucleus at 14 woa. E: Average percent FMN 
survival ± SEM, comparing the Ax to C facial motor nucleus at 6 wpo, corresponding with 14 
woa. Symbols used: *, p < 0.05. 
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